Gliobastoma multiforme (GBM) is an aggressive malignant form of brain tumour for which effective therapies are limited. Genetically engineered mouse models (GEMMs) harbouring mutations in components of the main signalling pathways that are altered in human GBM – including the receptor tyrosine kinase (RTK)–RAS– phosphoinositide-3-kinase (PI3K) pathway – are available. However, these GEMMs display a long latency to tumorigenesis and advanced tumour heterogeneity, which represents a challenge in preclinical drug testing. In this study, Zoë Weaver Ohler and colleagues developed an orthotopic and tractable mouse model of GBM by transplanting brain tumour cells derived from GBM-GEMMs into the brain (orthotopically) of syngeneic mice (non-transgenic wild-type mice with identical genetic backgrounds and intact immune systems). This model develops GBM with features of the human disease, including high vascularisation and aggressive invasion of surrounding tissues, and thus was used to test the effects of two drugs that are currently in clinical trials for GBM and other solid tumours, namely BKM120 and PD0325901 [inhibitors of PI3K and mitogen-activated protein kinase (MAPK), respectively]. When tested in vitro and in vivo as single agents, neither drug improved mouse survival. However, combination therapy increased cancer cell apoptosis, decreased tumour cell proliferation and enhanced survival, owing to a synergistic effect of the drugs on suppression of the PI3K pathway (which regulates cell proliferation and survival). Therefore, this model represents a valuable preclinical system for advancing current therapies and for testing novel drugs and drug combinations against GBM. Page 45
A preclinical model of glioblastoma
- Split-screen
- Views Icon Views
-
Article Versions Icon
Versions
- Version of Record 01 January 2015
- Share Icon Share
-
Tools Icon
Tools
- Search Site
A preclinical model of glioblastoma. Dis Model Mech 1 January 2015; 8 (1): e0102. doi:
Download citation file:
Advertisement
Cited by
Special Issue: The RAS Pathway

Our latest special issue is now complete. It showcases RAS-driven mechanisms of disease progression, and highlights approaches to treat and modify the disease course in model systems.
Call for papers: Moving Heart Failure to Heart Success

Disease Models & Mechanisms is pleased to welcome submissions for consideration for an upcoming special issue, Moving Heart Failure to Heart Success: Mechanisms, Regeneration & Therapy. Submission deadline: 4 July 2022.
Propose a new Workshop

Our Workshops bring together leading experts and early-career researchers from a range of scientific backgrounds. Applications are now open to propose Workshops for 2024, one of which will be held in a Global South country. .
A focus on Drosophila

In a series of front section articles, DMM is highlighting the versatility, breadth, and scope of Drosophila research in human disease modelling and translational medicine.
Apply for a DMM Conference Travel Grant

Aimed at early-career researchers wanting to attend in-person and virtual meetings, the next application deadline for a DMM Conference Travel Grant is 6 June 2022. Find out more and hear from past recipients about their experience of the grant.
Other journals from
The Company of Biologists